Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2019-09-18

Clinical Trial Update: Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia

View source ↗

Summary

A completed real-world study evaluating the effectiveness of paritaprevir/ritonavir-ombitasvir +/- dasabuvir +/- ribavirin in chronic hepatitis C patients in Co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dasabuvir (dasabuvir)
  • Ribavirin (ribavirin)
  • paritaprevir/ritonavir-ombitasvir (paritaprevir/ritonavir-ombitasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C | Status: COMPLETED | Results posted: 2019-09-18